SFRP1, an ADAM10 inhibitor, is elevated in the brains of patients with Alzheimer’s disease (AD). Antibody-mediated neutralization of its activity stalls brain alterations and cognitive loss in AD-like mice, supporting SFRP1 as a potential target for disease therapy.
- Pilar Esteve
- Javier Rueda-Carrasco
- Paola Bovolenta